Janssen has announced that its Janssen Human Microbiome Institute is forming a number of new collaborations focused on the creation of next-generation microbial products.
Together with the Janssen Disease Interception Accelerator, a new alliance with DayTwo and the Weizmann Institute of Science in Rehovot, Israel has been formed, with the aim of pursuing microbiome-based health solutions targeting metabolic disorders.
“Janssen has announced a series of new collaborations with DayTwo, the Weizmann Institute of Science and Caelus Health through its Janssen Human Microbiome Institute.“
In addition, with the scientific support of the Janssen Human Microbiome Institute and Bioqube Ventures, Caelus Health has been selected as a portfolio company of the Johnson and Johnson Innovation network.
Caelus becomes one of the first companies in Belgium to join the innovation community, which nurtures early-stage companies by providing access to resources to grow within the European life science ecosystem.
The overall aim of these collaborations will be to accelerate the translation of microbiome science into health solutions that can directly benefits patients.
Dr Dirk Gevers, global head of the Janssen Human Microbiome Institute, said: "By partnering with entrepreneurs, biotechs and academics and bringing innovative opportunities together with our expertise, we look to move microbiome science forward and deliver future solutions that promote individual health."
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Pharmaceutical